Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis.

ABSTRACT:

Background

Hepatitis B coinfection is common in HIV-positive individuals and as antiretroviral therapy has made death due to AIDS less common, hepatitis has become increasingly important. Several drugs are available to treat hepatitis B. The most potent and the one with the lowest risk of resistance appears to be tenofovir (TDF). However there are several questions that remain unanswered regarding the use of TDF, including the proportion of patients that achieves suppression of HBV viral load and over what time, whether suppression is durable and whether prior treatment with other HBV-active drugs such as lamivudine, compromises the efficacy of TDF due to possible selection of resistant HBV strains.

Methods

A systematic review and meta-analysis following PRISMA guidelines an

SUBMITTER: Price H 

PROVIDER: S-EPMC3707972 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature